BACKGROUND: N-terminal pro B-type natriuretic peptide (NT-proBNP) has strong prognostic value for all-cause mortality in the general population. High-sensitivity assays now allow detection of cardiac troponins even in asymptomatic populations. We examined the association between NT-proBNP, high-sensitivity cardiac troponin T (hs-cTnT), and hs-cTnI and all-cause mortality in older adults.
stress. They have been associated with different cardiac pathologies such as inflammation, ischemia, atrial fibrillation, fibrosis, and left ventricular (LV) hypertrophy (4 -6 ) . So far, single NT-proBNP measurements have shown strong prognostic value for all-cause mortality in the general population (7 ) . In addition, cardiac troponins T and I (cTnT and cTnI) are well-established biomarkers for the diagnosis of acute myocardial ischemia (8 ) . The use of high-sensitivity assays allows the detection of very low concentrations in asymptomatic individuals that are far below the diagnostic threshold. A higher prevalence of detectable troponin concentrations has been described among older individuals compared with the general population (9 ) . Detectable concentrations of troponins well below the diagnostic threshold have been associated with the presence of structural heart disease or high-risk phenotypes associated with cardiovascular disease (10 ) . Knowing that traditional risk factors such as hypertension and dyslipidemia do not show the same prognostic value for mortality among older adults as they do in the general population (11, 12 ) , we investigated the association of biomarker measurements by specific established and emerging cardiac biomarker assays [i.e., NT-proBNP, high-sensitivity (hs)-cTnT, and hs-cTnI] with the risk of death during 4-year follow-up in a large population-based cohort of noninstitutionalized older adults.
Methods

STUDY POPULATION
The Activity and Function in the Elderly in Ulm (ActiFE Ulm) study is a population-based cohort study in people Ն65 years old randomly selected in Ulm and adjacent regions in southern Germany. Exclusion criteria were severe deficits in cognition, vision, or hearing or serious German language difficulties. Between March 2009 and April 2010, 1506 eligible individuals provided written informed consent and underwent baseline assessments. Further details are described elsewhere (13 ) . The study was approved by the ethics committee of Ulm University. For the purposes of this study, those with missing information for biomarker concentrations (n ϭ 21) or important covariates [i.e., estimated glomerular filtration rate (eGFR) (n ϭ 22), handgrip strength (n ϭ 34), and comorbidities (n ϭ 7)] were excluded. Thus, a total of 1422 participants remained for this analysis.
DATA COLLECTION
The applied questionnaires included questions on sociodemographic characteristics, physical functioning, previous occurrence of falls, comorbidities, physical activity, clinical management, accessibility, and use of health services. Clinical assessment included anthropometrics, blood pressure, physical examination, handgrip strength, and blood sample collection.
LABORATORY METHODS
Blood was drawn at baseline, immediately centrifuged, aliquoted into multiple tubes, and stored at Ϫ80°C. Cholesterol and creatinine were measured the same day at the central laboratory of the University Hospital in Ulm from an unfrozen sample. Total cholesterol and HDL cholesterol (homogeneous method) were measured spectrophotometrically in a Dimension RxL Max Integrated Chemistry System (Siemens) on the basis of a reaction catalyzed by cholesterol oxidase, with Siemens reagents. Serum creatinine was measured with the kinetic Jaffe method (interassay CV 1.2%-3.0%) on a reference standard traceable to isotope-dilution mass spectrometry. C-reactive protein (CRP) was measured with a highsensitivity assay on a Behring Nephelometer II (interassay CV 5.2%-6.4%). For cardiac biomarkers, unthawed aliquots were used. NT-proBNP was measured in May 2011 with the ElectroChemiLuminescence ImmunoAssay (Elecsys 2010) proBNP II Test [CV Ͻ5%, lower limit of detection (LOD) 5 ng/L], which uses polyclonal antibodies (14 ) . We investigated the 8-year stability of NTproBNP in samples from another study with a maximum of 1 thaw cycle. The 8-year recovery was within the range of 89.5%-103.0%. hs-cTnT was measured in May 2011 with the Elecsys Troponin T hs Test (Roche Diagnostics), with LOD 5 ng/L and 10% CV 13 ng/L. The 99th percentile value is 10 ng/L for women and 15 ng/L for men. hs-cTnI was measured in January 2013 with the Architect STAT High Sensitivity Troponin-I Test (Abbott Diagnostics), with a within-laboratory imprecision of Յ10% CV across the range of 10 -50 000 ng/L (LOD 2.0 ng/L) and a reported within-run and withinlaboratory CV of Ͻ5.5%. Samples were thawed according to the process suggested by the manufacturer. The 99th percentile values are 24 ng/L for women and 36 ng/L for men. All markers were measured in a blinded fashion.
ASSESSMENT OF DEATHS
All study participants underwent a follow-up evaluation. We also contacted the registration offices to obtain information on changes of address and deaths, including date and district.
STATISTICAL ANALYSIS
Discrete variables are presented as counts and percentages, and continuous variables as arithmetic means and SDs or medians and interquartile ranges on the basis of their distribution. The median follow-up estimate was based on the reverse Kaplan-Meier estimator. We evaluated the demographic characteristics for the study population, for men vs women, and for deaths vs survivors. Using Cox proportional hazards models, we evaluated the association between each of the cardiac biomarkers as a continuous variable and the occurrence of death, adjusting initially for age and sex, followed by the multivariable analysis. There was evidence of effect modification by sex for all cardiac biomarkers (all P values Ͻ0.05). Owing to the low number of events among women, we report Cox proportional hazards models after categorization and death only for men. We further adjusted for ln(CRP) and evaluated the association of NT-proBNP after including ln(hs-cTnT) and ln(hs-cTnI) in the model, as well as the association for hs-cTnT after additional adjustment for hs-cTnI, and vice versa. Any improvement in the models was evaluated with respect to discrimination and calibration. The latter was performed with the Hosmer-Lemeshow 2 statistic, which assesses whether the observed event rates match expected event rates (a statistically significant P value indicates a poor calibration). NT-proBNP was categorized into quartiles. For hs-cTnI, we identified those with hs-cTnI higher than the sex-specific 99th percentile (Ն34 ng/L) (category 5), categorizing the rest of the sample by quartiles (categories 1, 2, 3, and 4). Category 1 includes the 5 individuals with hs-cTnI Ͻ2 ng/L. These measurements were set a value of 1.0 ng/L as recommended (16 ) . For hs-cTnT, the reference category 1 contains those individuals with concentrations Ͻ5 ng/L (nondetectable), and category 4 those with concentrations higher than the 99th percentile (Ն14 ng/L), with the rest of the sample dichotomized into categories 2 and 3. A total of 777 participants showed hs-cTnT Ͻ5 ng/L. These measurements were set a value of 2.5 ng/L as recommended (16 ) . In this subgroup, we examined the association of ln(hscTnI) with death after adjustment for age and sex. Owing to the low number of events, a sex-stratified analysis was not feasible (13 deaths among 331 men, 5 deaths among 446 women). All analyses were performed with SAS version 9.2.
Results
In total, 1422 older adults were included in this analysis. Table 1 shows the baseline characteristics of the participants. Mean age was 75.5 years; 56.5% were men; mean BMI was 27.6 kg/m 2 , with 49.4% being overweight and 24.7% obese. There were 340 participants (23.9%) living alone, and 18 (1.3%) reported the use of a walking aid. Four hundred eighty-four (34.0%) reported no comorbidities, with 549 (38.6%), 270 (19.0%), and 120 (8.4%) reporting 1, 2, and Ն3 comorbidities, respectively. A history of hypertension, heart failure, diabetes, and myocardial infarction was reported by 53.7%, 14.6%, 13.3%, and 8.4% of participants, respectively. Men were more likely to be older, overweight, and smokers or former smokers; have 2 or more comorbidities; and have increased systolic blood pressure, decreased total and HDL cholesterol, and higher troponin concentrations. Women had decreased handgrip strength on average. A higher proportion of women compared with men had Ͻ9 years of education, had a history of myocardial infarction or diabetes, and were living alone.
The median concentration of NT-proBNP was 153 ng/L. The distribution of cardiac troponins varied between sexes. Men had statistically significantly higher median hs-cTnT compared with women (6.4 vs 2.5 ng/L). The median hs-cTnI was 5.9 ng/L, with concentrations higher among men (6.8 vs 5.1 ng/L in women). Fig. 1 displays the distribution of hs-cTnT and hscTnI concentrations stratified by sex. hs-cTnT and hscTnI correlated only moderately (age-and sex-adjusted Spearman coefficient 0.46). Supplemental Tables 1 and  2 , which accompany the online version of this article at http://www.clinchem.org/content/vol61/issue2, provide detailed information on the median concentrations of the cardiac biomarkers among various sociodemographic characteristics and established risk factors.
A total of 125 participants died during the median 4-year follow-up (interquartile range 3.8 -4.3 years). The incidence rate was 22.7 deaths per 1000 person-years (95% CI 19.0 -27.0). Compared with survivors, those who died were more likely to be older, be male, live alone, use walking aids, and have 2 or more comorbidities, decreased handgrip strength, decreased eGFR, decreased total and HDL cholesterol, higher concentrations of all cardiac biomarkers, and higher concentrations of CRP (see online Supplemental Table 2 ). We observed a total of 88 deaths among 804 men and 37 deaths among 618 women, resulting in a rate of 28.6 deaths per 1000 person-years (95% CI 23.1-35.0) and 15.3 deaths per 1000 person-years (95% CI 10.9 -20.8), respectively (median follow-up 4.0 years). As displayed in Table 3 , a 1-unit increment of ln(NT-proBNP) was associated with an HR of 1.73 (95% CI 1.40 -2.13) in multivariable analysis (model 2). After further adjustment for ln(CRP) and ln(hstroponins) a 1-unit increment of ln(NT-proBNP) was still associated with a 31% increased hazard for death (HR 1.31, 95% CI 1.05-1.65, model 6). Using quartiles, we observed an HR of 3.57 (95% CI 1.50 -8.51, model 2) for those in the upper quartile compared with the bottom one. This association was attenuated but remained statistically significant after additional adjustment for ln(CRP) and ln(hs-cTnT) (HR 2.41, 95% CI 1.01-5.77, model 4). Table 4 presents the results for hs-troponins. A1-unit increment of ln(hs-cTnT) was associated with an HR for death of 2.15 (95% CI 1.61-2.87, model 2) in multivariable analysis, whereas those with hs-cTnT Ն14 ng/L (category 4) had a 3.21 times increased risk of dying (95% CI 1.55-6.63) compared with those with undetectable hs-cTnT (model 2). A 1-unit increment of ln(hscTnT) was still associated with a 64% increased hazard for death after further adjustment for ln(CRP) and ln(NT-proBNP) (HR 1.64, 95% CI 1.21-2.24, model 4). This association became nonsignificant with additional adjustment for ln(hs-cTnI).
A 1-unit increment of ln(hs-cTnI) was associated with an HR for death of 1.92 (95% CI 1.55-2.38) in multivariable analysis (model 2). This association was attenuated but remained statistically significant after further adjustment for ln(CRP), ln(NT-proBNP), and Table 5 summarizes the improvement in discrimination achieved after addition of the cardiac biomarkers among men, with the model containing ln(NTproBNP), ln(CRP), and ln(hs-cTnI) having the best c-statistic and a good calibration.
Discussion
Our prospective study including 1422 communitydwelling older adults showed independent and sex-specific associations between NT-proBNP and hs-troponins with the risk of death during a 4-year follow-up, even after controlling for established risk factors, including a marker of inflammation. We detected marked differences in the distribution of cardiac troponins between sexes and effect modification by sex for all cardiac biomarkers, with stronger associations among women compared with men. Therefore, NT-proBNP, hs-cTnT, and hs-cTnI are important predictors not only for cardiovascular diseases, but also for total mortality. Integrated into a comprehensive geriatric assessment, they could serve as additional prognostic markers providing support to caregivers with respect to medical decisions.
Our results are in concordance with the literature, where NT-proBNP has been shown to be a strong predictor for all-cause mortality in older adults with and without cardiovascular diseases (17, 18 ) . Among cardiac patients, increased NT-proBNP has been associated with inflammation, ischemia, atrial fibrillation, fibrosis, and LV hypertrophy (4 ) . In asymptomatic subjects, high NT-proBNP could reflect subclinical levels of ventricular dysfunction or inducible ischemia (7, 19 ) , as well as the presence of vascular dysfunction or atherosclerosis progression (20 ) , inclusive cerebral ischemia, and neurologic deficits (21 ) . The observed effect modification for NTproBNP by sex merits further investigation. In this respect, it has been hypothesized that a lower cardiovascular risk among fertile women could be related in part to differences in the stimulatory effect of steroid hormones on the cardiac endocrine function, where estrogens may have a stimulatory and androgens an inhibitory action (22 ) .
Distributions of cardiac troponins as shown in our study have already been described (11, 20, (23) (24) (25) . However, so far, no explanation has been found for the observed higher cardiac troponin concentrations in men compared with women (26 ) . These divergences have been related to intrinsic differences in the amount of cardiac troponins between the male and female myocardium, as well as to differences in the pathogenesis of coronary artery disease, with women presenting more often with endothelial dysfunction instead of the fixed coronary disease more often seen among men (27 ) . Differences in the performance of cTnT among younger and older patients have also been described (24 ) , and the need for age-and sex-dependent cutoffs for hs-troponins is presently under intense discussion.
An association between increased concentrations of cTnT and the subsequent risk for all-cause mortality after additional adjustment for traditional risk factors including CRP has already been reported (25, 28 ) , suggesting that this biomarker may predict structural heart disease events to a greater extent than atherosclerotic events (25 ) . Increased troponin T may also be related to microvascular coronary disease present in coronary heart disease, Table 5 . Assessing model discrimination and calibration among men (n = 804). diabetes mellitus, chronic kidney disease, LV strain, decreased subendocardial perfusion, endothelial dysfunction, and apoptosis present in heart failure (29 ) . Furthermore, oxidative stress injury or inflammation induced by prolonged episodes of supraventricular tachyarrhythmias, even in presumably healthy individuals, might play a role (30 ) . Particularly in elderly people, hs-cTnT seems to increase gradually in relation to small changes in LV mass or isolated LV diastolic dysfunction. When comparing hs-cTnT and NT-proBNP with respect to their association with cardiac phenotype, no differences between markers have been reported among men. Among women, however, stepwise changes in the cardiac markers with minimal deteriorations in LV structure or function have been noted to be more pronounced for hscTnT than for NT-proBNP (31 ) . Increased hs-cTnI has been more frequently reported in males and people with cardiovascular risk factors or comorbidities. Increases, particularly in older adults, have been associated with male sex, NT-proBNP, and LV mass index. It has been postulated that the unexpected increasing concentrations of hs-cTnI may reflect a continuous increasing degree of impaired cardiac integrity, even in the absence of ischemic damage of the myocardium (32 ) . This is in concordance with our results, where we observed a linear relationship between ln(hs-cTnI) and the risk of death even after additional adjustment for ln(CRP), ln(NT-proBNP), and ln(hscTnT). Of note, in those with undetectable hs-cTnT (Ͻ5 ng/L), hs-cTnI was still predictive for death.
The synergism observed in this analysis between hscTnT and hs-cTnI is not easily explainable. Although both troponins are similar in many ways, they are, after all, different analytes. Both are present in cardiac and skeletal muscles but are encoded by different genes in the 2 types of muscles. The majority of cardiac troponin is bound to myofilaments, and only about 5%-8% is free in the cytosol. When myocyte damage occurs, the cytosolic pool is released first, followed by a more protracted release from stores bound to deteriorating myofilaments (33 ) . Different hypotheses have been offered to explain very low, but detectable, cardiac troponin concentrations, not only in the elderly but also among healthy children (34 ) . Such findings may merely reflect the routine biological process of myocyte turnover (30 ) . Exercise-induced cardiac ischemia can also lead transiently to very small increases in cardiac troponins (35, 36 ) for reasons that are controversial (37 ) . Although in many studies hs-cTnT and hs-cTnI appear similar, those studies are mostly on the basis of patients with ischemic heart disease, and there may be other differences in more chronic, nonischemic situations.
One possibility that should be considered is that some of the cTnT observed may come from skeletal muscle. In utero, cTnT is detected not only in heart but also in skeletal muscles. After birth, it gradually disappears from skeletal muscle and can no longer be detected in healthy skeletal muscle. However, once a regeneration process in the skeletal muscle is initiated owing to muscular injury, a reexpression of fetal proteins has been described, so that diseased skeletal muscle contains cTnT in addition to the skeletal muscle troponins T and I (38 ) . Whereas myocardial injury causes the simultaneous release of both cTnI and cTnT into the circulation, chronic injury to skeletal muscle has been associated with the release of cTnT but not cTnI, as predicted by their different biological expressions (39 ) . So far, the question whether the available assays cross-react with cTnT or its isoforms in diseased skeletal muscle has not been well addressed (40 ) . This question becomes particularly relevant in the observed low correlation and prognostic synergism between hs-cTnI and hs-cTnT and requires further investigation.
Our study has several strengths and limitations. The sampling method that we used gave a balanced distribution of individuals across all age strata and both sexes. We had information on well-established risk factors for death and cardiovascular diseases in older people. Among the limitations, the initial low participation rate with a higher representation of older men might limit the generalizability of the results, but it should not be a threat to the internal validity of our study results. We did not have cause-specific data, and therefore a stratified analysis comparing cardiovascular vs noncardiovascular deaths was not possible. We did not have information on the presence of chronic myopathies to explore a possible association of this pathology with an increased ratio of troponins (cTnT/cTnI). We also lacked information on structural and functional changes of the heart at baseline, making it impossible to explore the associations of the cardiac biomarkers and the respective baseline phenotypes.
In conclusion, our prospective study in communitydwelling older adults showed a positive independent association between NT-proBNP, hs-cTnT, and hs-cTnI and the occurrence of death during a 4-year follow-up. Effect modification was detected between sexes, with stronger associations observed among women. Given that the identification of medical comorbidities is 1 of the objectives of a comprehensive geriatric assessment, it would be important to further evaluate the sex-specific prognostic value of these cardiac biomarkers with respect to both cardiovascular disease and subclinical structural heart disease, and with respect to death and the onset of disability in these settings.
